A UW-Madison researcher has developed a web-based atlas of cell surface target (CST) protein expression across various cancer types. This system can be used to identify understudied drug targets for t...
Learn More

UW-Madison researchers have developed a glioblastoma cancer vaccine using primary tumor cells transfected with a genetic construct expressing a fusion of IL-7 and GM-CSF. The transfected cells are tre...
Learn More

UW-Madison researchers have developed a protein degrader that shuttles targeted extracellular protein into the lysosome using a cyclic peptide that binds to a cellular receptor attached to a binding m...
Learn More

UW-Madison researchers have developed an AI-based method for designing humanized CAR sequences. Using this method, they developed two novel humanized CD19 sequences that can be used for production of ...
Learn More

A UW-Madison researcher has developed an oral combination therapy for treating fibrolamellar carcinoma (FLC) that utilizes a CDK7 inhibitor and a CDK9 inhibitor. The researcher created a cancer cell l...
Learn More

UW-Madison researchers in collaboration with researchers at the Oak Ridge National Laboratory have developed chelated antimony (Sb) that can be used for targeted Auger radiotherapy. While 119Sb has be...
Learn More

UW-Madison researchers have developed a non-viral method of developing CAR NK cells. The inventors tested many parameters along established processes for genetically modifying immune cells without vir...
Learn More

UW-Madison researchers have developed a focused library of CARM1 protein degraders. These degraders used a known binding molecule of CARM1 with an optimized linker attached to a Von Hippel–Lindau (V...
Learn More

UW-Madison researchers have developed a new CAR T cell technology to be used in combination with targeted radionuclide treatment for treating sold tumors. The patient is dosed with low dose targeted r...
Learn More

UW-Madison researchers have developed a novel camelid antibody against the cancer target cMET. As cMET is overexpressed on many tumors, this antibody may be useful for imaging tumors and/or delivering...
Learn More

UW-Madison researchers have developed a protein degrader that shuttles targeted extracellular protein into the lysosome using a cyclic peptide that binds to a cellular receptor attached to a binding m...
Learn More

The development of small-molecule compounds that target the murine double minute 2 protein (MDM2) represents a significant advancement in cancer therapy. MDM2 is known to inhibit the tumor suppressor ...
Learn More

UW-Madison researchers have developed an improved delivery system that is able to penetrate the extracellular matrix (ECM) and shuttle surface-conjugated protein cages, composed of collagenases and an...
Learn More

UW-Madison researchers have developed ferritin-targeting proteolysis targeting chimeras (PROTACs) to establish an iron excess stress inside cancer cells. The PROTAC structure contains oleic acid for b...
Learn More

UW researchers have created a biological therapeutic that stimulates the immune system to fight solid tumors. The researchers fused the cytokines IL-6 and IL- together to form a bifunctional biomol...
Learn More

UW researchers have identified a molecule commonly used as a vaccine adjuvant to add to the combination of radiation therapy and checkpoint inhibitor treatment to drive the immune system’s response ...
Learn More

UW researchers have identified a molecule commonly used as a vaccine adjuvant to add to the combination of radiation therapy and checkpoint inhibitor treatment to drive the immune system’s response ...
Learn More

UW-Madison researchers have developed a novel approach for enhancing pyroptosis, which could prove beneficial in treating cancer. The inventors combine intracellular delivery of gasdermin with a small...
Learn More

Theranostics, a term derived from a combination of therapeutics and diagnostics, is an emerging field of medicine where specific radionuclide disease-targeting agents are used to diagnose and treat me...
Learn More

The present technology from UW Madison inventors provides nanoparticles comprising a positively charged polymer (e.g., polylysine) electrostatically bound to iron oxide nanoparticles and CpG oligodeox...
Learn More

Ex vivo expansion and activation of T cells are prerequisites for any form of genetically engineered T cell immunotherapy. Several expansion and activation methodologies have been developed. However, ...
Learn More

Use of viral vectors for chimeric antigen receptor (CAR) T cell manufacturing constitutes a bottleneck in the supply chain for biomanufacturing and can be problematic due to: (1) batch-to-batch variab...
Learn More

UW-Madison researchers have developed a nanoparticle-based platform comprising targeting agents (i.e., tumor selective peptides) and active agents (e.g., immuno- and chemo-drugs).  The nanoparticles ...
Learn More

The present invention from UW Madison researchers provides in vitro derived a multicell conjugate comprising an iNKT cell and a dendritic cell (DC). The invention also provides methods of making the m...
Learn More

Currently there are no cell therapies approved for use against acute radiation injury (ARS). Severe ARS can cause death and the only cell treatment is allogenic bone marrow transplantation (BMT). Unfo...
Learn More